DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • India
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
540359 logo

Parmax Pharma Limited Stock Price

BSE:540359 Community·₹920.1m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

540359 Share Price Performance

₹133.75
99.60 (291.65%)
​
₹133.75
99.60 (291.65%)
​
Price ₹133.75
Fri, 11 Sep 26
Share Pricen/a

540359 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Low risk with weak fundamentals.

3 Risks
0 Rewards
View Full Analysis

Parmax Pharma Limited Key Details

₹0

Revenue

₹0

Cost of Revenue

₹0

Gross Profit

₹0

Other Expenses

₹0

Earnings

Last Reported Earnings
n/a
Next Reporting Earnings
n/a
0
0%
0%
0%
View Full Analysis

About 540359

Founded
1994
Employees
n/a
CEO
Umang Gosalia
WebsiteView website
www.parmaxpharma.com

Parmax Pharma Limited operates in the pharmaceutical business in India. It manufactures and sells bulk drugs, drug intermediates, and specialty chemicals. The company was incorporated in 1994 and is based in Rajkot, India.

Recent 540359 News & Updates

Recent updates

No updates

Parmax Pharma Limited Competitors

SAILIFE logo

Sai Life Sciences

Symbol: NSEI:SAILIFE
Market cap: ₹336.2b
RUBICON logo

Rubicon Research

Symbol: NSEI:RUBICON
Market cap: ₹303.8b
524558 logo

Neuland Laboratories

Symbol: BSE:524558
Market cap: ₹302.0b
PPLPHARMA logo

Piramal Pharma

Symbol: NSEI:PPLPHARMA
Market cap: ₹280.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide